ライフサイエンスコーパス: riociguat

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 lmonary endarterectomy to receive placebo or riociguat.

2 ing the soluble guanylate cyclase stimulator riociguat.

3 double-blind treatment with oral placebo or riociguat (0.5, 1, or 2 mg 3 times daily) for 16 weeks i

4 ase in mean pulmonary artery pressure in the riociguat 2 mg group (-6.1+/-1.3 mm Hg; P<0.0001 versus

5 3; P=0.0002) were significantly reduced with riociguat 2 mg.

6 Riociguat, a member of a new class of compounds (soluble

7 We hypothesized that riociguat, a novel soluble guanylate cyclase stimulator,

8 Riociguat, a soluble guanylate cyclase stimulator, has b

9 ronic thromboembolic pulmonary hypertension, riociguat, a stimulator of soluble guanylate cyclase, ha

10 protective effects triggered by cinaciguat, riociguat, and different phosphodiesterase-5 inhibitors

11 of CHEST-2, where most patients had received riociguat for at least 2 years.

12 nts in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group).

13 tance decreased by 226 dyn.sec.cm(-5) in the riociguat group and increased by 23 dyn.sec.cm(-5) in th

14 tance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m

15 Prespecified subgroup analyses showed that riociguat improved the 6-minute walk distance both in pa

16 riociguat monotherapy and 199 were receiving riociguat in combination with endothelin receptor antago

17 ry arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg

18 three times daily (2.5 mg-maximum group), or riociguat in individually adjusted doses that were cappe

19 ding pharmacological profile, application of riociguat in other cardiovascular indications is limited

20 These results support the long-term use of riociguat in patients with pulmonary arterial hypertensi

21 th pulmonary arterial hypertension receiving riociguat in the PATENT-2 study.

22 ension study, in which all patients received riociguat individually adjusted to a maximum dose of 2.5

23 All patients received riociguat individually adjusted to a maximum dose of 2.5

24 Riociguat may be used long term in patients with CTEPH.

25 ATENT-2, of whom 197 patients were receiving riociguat monotherapy and 199 were receiving riociguat i

26 Riociguat reduced the Minnesota Living With Heart Failur

27 Riociguat significantly improved exercise capacity and p

28 Riociguat significantly improved exercise capacity and s

29 %) of 237 patients, and 14 (6%) discontinued riociguat therapy because of adverse events.

30 st patients had received at least 2 years of riociguat treatment.

31 Riociguat was also associated with significant improveme

32 s soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment o

33 Riociguat was well tolerated by most patients and no new

34 Riociguat was well tolerated in PATENT-2.

35 primary end point of the study was not met, riociguat was well tolerated in patients with pulmonary

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。